{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T02:07:06Z","timestamp":1780106826813,"version":"3.54.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T00:00:00Z","timestamp":1767139200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006501","name":"Cystic Fibrosis Foundation Therapeutics Lab","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006501","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["PCT\/US2023\/075747"],"award-info":[{"award-number":["PCT\/US2023\/075747"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["US 63\/412771"],"award-info":[{"award-number":["US 63\/412771"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Nucleic Acids"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.omtn.2025.102829","type":"journal-article","created":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T23:51:48Z","timestamp":1767397908000},"page":"102829","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Upregulation of a CFTR mRNA isoform has therapeutic potential for the treatment of 3\u2032 CFTR PTC variants"],"prefix":"10.1016","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3497-8459","authenticated-orcid":false,"given":"Normand E.","family":"Allaire","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew S.","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Seok","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mercy C.","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyanka","family":"Bhatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan M.","family":"Harrington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric I.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John E.","family":"Mahoney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hillary C.","family":"Valley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlin M.","family":"Macadino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermann J.","family":"Bihler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrey Y.","family":"Sivachenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Calvin U.","family":"Cotton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P.","family":"Carulli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Mense","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtn.2025.102829_bib1","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.3390\/cells10102793","article-title":"Therapeutic Approaches for Patients with Cystic Fibrosis Not Eligible for Current CFTR Modulators","volume":"10","author":"Fajac","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.omtn.2025.102829_bib2","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1164\/rccm.201009-1478CI","article-title":"Managing cystic fibrosis: strategies that increase life expectancy and improve quality of life","volume":"183","author":"Cohen-Cymberknoh","year":"2011","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.omtn.2025.102829_bib3","doi-asserted-by":"crossref","first-page":"18825","DOI":"10.1073\/pnas.0904709106","article-title":"Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, IVA","volume":"106","author":"Van Goor","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtn.2025.102829_bib4","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1056\/NEJMoa1709846","article-title":"Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del","volume":"377","author":"Taylor-Cousar","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omtn.2025.102829_bib5","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jcf.2016.09.005","article-title":"Therapeutic benefit observed with the CFTR potentiator, ivacaftor, in a CF patient homozygous for the W1282X CFTR nonsense mutation","volume":"16","author":"Mutyam","year":"2017","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.omtn.2025.102829_bib6","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1165\/rcmb.2006-0176OC","article-title":"Restoration of W1282X CFTR activity by enhanced expression","volume":"37","author":"Rowe","year":"2007","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"10.1016\/j.omtn.2025.102829_bib7","series-title":"A Dissertation Submitted to the Faculty of the University of North Carolina at Chapel Hill in Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy in the Curriculum of Genetics and Molecular Biology","article-title":"Tissue specific form of CFTR","author":"Burch","year":"2001"},{"key":"10.1016\/j.omtn.2025.102829_bib8","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.jcf.2018.12.001","article-title":"Isogenic cell models of cystic fibrosis-causing variants in natively expressing pulmonary epithelial cells","volume":"18","author":"Valley","year":"2019","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.omtn.2025.102829_bib9","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1177\/2472630317692561","article-title":"High-throughput screening for readthrough modulators of CFTR PTC mutations","volume":"22","author":"Liang","year":"2017","journal-title":"SLAS Technol."},{"key":"10.1016\/j.omtn.2025.102829_bib10","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1111\/bph.14141","article-title":"Partial rescue of F508del-cystic fibrosis transmembrane conductance regulator channel gating with modest improvement of protein processing, but not stability, by a dual-acting small molecule","volume":"175","author":"Liu","year":"2018","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.omtn.2025.102829_bib11","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1074\/jbc.M116.764720","article-title":"Correctors and Potentiators Rescue Function of the Truncated W1282X-Cystic Fibrosis Transmembrane Regulator (CFTR) Translation Product","volume":"292","author":"Haggie","year":"2017","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.omtn.2025.102829_bib12","doi-asserted-by":"crossref","first-page":"444","DOI":"10.3109\/10409238.2012.694846","article-title":"Suppression of premature termination codons as a therapeutic approach","volume":"47","author":"Keeling","year":"2012","journal-title":"Crit. Rev. Biochem. Mol. Biol."},{"key":"10.1016\/j.omtn.2025.102829_bib13","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s10020-018-0024-7","article-title":"Advances in therapeutic use of a drug-stimulated translational readthrough of premature termination codons","volume":"24","author":"Dabrowski","year":"2018","journal-title":"Mol. Med."},{"key":"10.1016\/j.omtn.2025.102829_bib22","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1073\/pnas.51.5.883","article-title":"Streptomycin, suppression, and the code","volume":"51","author":"Davies","year":"1964","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtn.2025.102829_bib30","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1073\/pnas.1220256110","article-title":"Molecular dissection of dystrophin identifies the docking site for nNOS","volume":"110","author":"Harper","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtn.2025.102829_bib14","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1021\/bi00568a029","article-title":"Triphasic concentration effects of gentamicin on activity and misreading in protein synthesis","volume":"18","author":"Tai","year":"1979","journal-title":"Biochemistry"},{"key":"10.1016\/j.omtn.2025.102829_bib15","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/0014-5793(84)80994-1","article-title":"Increased translational fidelity caused by the antibiotic kasugamycin and ribosomal ambiguity in mutants harbouring the ksgA gene","volume":"177","author":"van Buul","year":"1984","journal-title":"FEBS Lett."},{"key":"10.1016\/j.omtn.2025.102829_bib16","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1017\/S1355838200000716","article-title":"Aminoglycoside antibiotics mediate context-dependent suppression of termination codons in a mammalian translation system","volume":"6","author":"Manuvakhova","year":"2000","journal-title":"RNA"},{"key":"10.1016\/j.omtn.2025.102829_bib17","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/ki.2010.337","article-title":"New insights into the mechanism of aminoglycoside nephrotoxicity: an integrative point of view","volume":"79","author":"Lopez-Novoa","year":"2011","journal-title":"Kidney Int."},{"key":"10.1016\/j.omtn.2025.102829_bib18","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1093\/infdis\/119.4-5.406","article-title":"Nephrotoxicity of aminoglycosides and gentamicin","volume":"119","author":"Falco","year":"1969","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.omtn.2025.102829_bib19","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1006\/jmbi.1995.0438","article-title":"The efficiency of translation termination is determined by a synergistic interplay between upstream and downstream sequences in Saccharomyces cerevisiae","volume":"251","author":"Bonetti","year":"1995","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.omtn.2025.102829_bib20","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1471-2199-2-3","article-title":"UAG readthrough in mammalian cells: effect of upstream and downstream stop codon contexts reveal different signals","volume":"2","author":"Cassan","year":"2001","journal-title":"BMC Mol. Biol."},{"key":"10.1016\/j.omtn.2025.102829_bib21","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/wrna.116","article-title":"Signals for pre-mRNA cleavage and polyadenylation","volume":"3","author":"Tian","year":"2012","journal-title":"Wiley Interdiscip. Rev. RNA"},{"key":"10.1016\/j.omtn.2025.102829_bib24","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1101\/sqb.2019.84.040451","article-title":"U1 snRNP Telescripting Roles in Transcription and Its Mechanism","volume":"84","author":"Di","year":"2019","journal-title":"Cold Spring Harb. Symp. Quant. Biol."},{"key":"10.1016\/j.omtn.2025.102829_bib23","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1038\/nature09479","article-title":"U1 snRNP protects pre-mRNAs from premature cleavage and polyadenylation","volume":"468","author":"Kaida","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.omtn.2025.102829_bib25","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jcf.2015.02.002","article-title":"Comparative ex vivo, in vitro and in silico analyses of a CFTR splicing mutation: Importance of functional studies to establish disease liability of mutations","volume":"15","author":"Ramalho","year":"2016","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.omtn.2025.102829_bib26","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1177\/1060028018789956","article-title":"Nusinersen: A Treatment for Spinal Muscular Atrophy","volume":"53","author":"Claborn","year":"2019","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.omtn.2025.102829_bib27","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.jcf.2021.06.003","article-title":"Antisense oligonucleotide-based drug development for Cystic Fibrosis patients carrying the 3849+10 kb C-to-T splicing mutation","volume":"20","author":"Oren","year":"2021","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.omtn.2025.102829_bib31","article-title":"Exon-skipping antisense oligonucleotides for cystic fibrosis therapy","volume":"119","author":"Kim","year":"2022","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtn.2025.102829_bib32","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.1038\/s41467-022-30668-y","article-title":"Gene-specific nonsense-mediated mRNA decay targeting for cystic fibrosis therapy","volume":"13","author":"Kim","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtn.2025.102829_bib33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1513\/AnnalsATS.201708-668PS","article-title":"The U.S. Food and Drug Administration\u2019s Experience with Ivacaftor in Cystic Fibrosis. Establishing Efficacy Using In Vitro Data in Lieu of a Clinical Trial","volume":"15","author":"Durmowicz","year":"2018","journal-title":"Ann. Am. Thorac. Soc."},{"key":"10.1016\/j.omtn.2025.102829_bib28","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2023.1276144","article-title":"Detecting early signs in Duchenne muscular dystrophy: comprehensive review and diagnostic implications","volume":"11","author":"Mercuri","year":"2023","journal-title":"Front. Pediatr."},{"key":"10.1016\/j.omtn.2025.102829_bib29","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ymthe.2006.01.007","article-title":"C-terminal-truncated microdystrophin recruits dystrobrevin and syntrophin to the dystrophin-associated glycoprotein complex and reduces muscular dystrophy in symptomatic utrophin\/dystrophin double-knockout mice","volume":"14","author":"Yue","year":"2006","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2025.102829_bib34","series-title":"R: A Language and Environment for Statistical Computing","year":"2024"}],"container-title":["Molecular Therapy Nucleic Acids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S216225312500383X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S216225312500383X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T01:16:13Z","timestamp":1780103773000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S216225312500383X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S216225312500383X"],"URL":"https:\/\/doi.org\/10.1016\/j.omtn.2025.102829","relation":{},"ISSN":["2162-2531"],"issn-type":[{"value":"2162-2531","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Upregulation of a CFTR mRNA isoform has therapeutic potential for the treatment of 3\u2032 CFTR PTC variants","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Nucleic Acids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtn.2025.102829","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"102829"}}